NDAORALCAPSULE, EXTENDED RELEASE
Approved
Mar 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
INNOPRAN XL (propranolol hydrochloride) by ANI Pharmaceuticals is established. First approved in 2003.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INNOPRAN XL is an extended-release oral capsule formulation of propranolol hydrochloride, a non-selective beta-blocker approved in 2003. It reduces blood pressure through decreased cardiac output, inhibition of renin release, and diminished sympathetic nerve outflow. Indicated for hypertension management in patients requiring once-daily dosing.
$0.003BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Medicare utilization signals small brand team and defensive commercial focus.
Mechanism of Action
established. Among factors that contribute to the antihypertensive action are: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
Started Nov 2024
6 enrolled
Non Small Cell Lung CancerPropranolol
Career Relevance
Working on INNOPRAN XL offers exposure to mature product management in a competitive generic-dominated marketplace and practical experience in LOE strategy and defensive positioning. Career growth potential is limited by product maturity; roles emphasize cost containment, payer relations, and market share defense rather than innovation or expansion.
Worked on INNOPRAN XL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.